EXPANDED IVD TIER I LIST BASED ON NCCLS STANDARDS ENDORSED BY FDA; WORKSHOP PANELISTS OPPOSE ADDING POINT-OF-CARE, PHYSICIAN-OFFICE TESTS TO TIER I
This article was originally published in The Gray Sheet
Executive Summary
FDA may be willing to move more in vitro diagnostics into the least stringent premarket review "tier" (Tier I) if the National Committee for Clinical Laboratory Standards develops review criteria for the products, Steve Gutman, director of the device center's Division of Clinical Laboratory Devices (DCLD) said at an Oct. 30 workshop in Rockville, Maryland.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Nominates Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.